Navigation Links
Patients' underlying health linked to worse outcomes for melanoma, U-M study finds
Date:8/30/2011

ANN ARBOR, Mich. It's not how old but how frail patients are that can predict how well they will fare after a melanoma diagnosis. In fact, young patients in poor health may have worse outcomes than older patients in good shape.

A new study from the University of Michigan Comprehensive Cancer Center finds that patients with decreased core muscle density were more likely to see their cancer spread to distant parts of the body.

These findings may also support the idea that the patient's biological response to a tumor is important in controlling the spread of melanoma. Patients whose systems are less able to mount a response may be more prone to their cancer spreading.

The researchers believe that identifying those patients who are at higher risk of poor outcomes could impact treatment decisions, including the success of new immunotherapy drugs. And potentially, if this degenerative muscle loss, called sarcopenia, can be reversed, patients might have better outcomes.

The study, which appears online in Annals of Surgical Oncology, looked at 101 patients treated for stage III melanoma at the U-M Comprehensive Cancer Center. Researchers examined CT scans for each patient to measure the area and density of a core muscle called the psoas, which runs along both sides of the spine.

They found that patients with lower muscle density had significantly higher rates of their cancer returning regardless of factors such as the size of the tumor or the patient's age. Every 10 units of decreased muscle density translated to a 28 percent increase in recurrence. In addition, frailer patients had more complications from surgery to remove their cancerous lymph nodes.

Research has previously linked older age to worse outcomes in melanoma. These new results distinguish that it's the underlying vitality of the patient, not age, that really matters.

Many studies have looked at ways to reverse sarcopenia by focusing on diet and exercise.

"The big question is if we could reverse sarcopenia through better nutrition and exercise, would that lead to a decreased risk of recurrence in those patients?" says lead study author Michael S. Sabel, M.D., associate professor of surgery at the U-M Medical School.

In addition, researchers hope this information will help explain the limited success of new immunotherapy or cancer vaccine treatments.

"The data suggests that frailer patients may be less likely to respond to these forms of therapy. It is very possible that prior trials of vaccines or other immune therapies that didn't show an effect would have shown an effect if we had weeded out the patients unlikely to respond to therapy," Sabel says.

Researchers plan next to look at CT scans from patients treated in these trials to analyze whether the treatments were more effective in patients without sarcopenia.

Melanoma statistics: 68,130 Americans will be diagnosed with melanoma this year and 8,700 will die from the disease, according to the American Cancer Society


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Transcatheter aortic valve implantation with the Edwards valve prosthesis in patients with low
2. What do patients receiving optimal medical therapy after a heart attack die from?
3. Potential benefits of remote follow-up of ICD patients
4. Clinical outcomes in PCI patients given sirolimus-eluting and everolimus-eluting stents
5. Patients are living longer with ICDs, but pacing impacts survival rates
6. Temporary ER staff poses increased safety risk to patients
7. Uninsured trauma patients are more likely to use the ED for follow-up care
8. Dialysis Patients Unprepared for Disasters, Study Contends
9. Achieving realistic physical activity goals benefits RA patients
10. Bone marrow transplantation may increase cancer resistance in patients
11. Clinical trial shows benefit to adding avastin to neoadjuvant chemotherapy in breast cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, ... with The Jensie Gran Fondo of Marin. For the second year in a ... broad-spectrum, mineral-based sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen ...
(Date:2/23/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Beach to host its Swirl: Miami Wine Tasting Event on March 28, 2017. ...
(Date:2/23/2017)... ... 23, 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. ... Not to Hot,” which will begin airing on February 24, 2017. The show chronicles ... the 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series from ...
(Date:2/23/2017)... ... 2017 , ... EBSCO Information Services (EBSCO) has ... Health and Care Excellence (NICE) framework. The agreement allows purchasers from libraries, ... search, order and purchase medical and healthcare-related content through GOBI ®, the ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing ... generations converge and explore the world from different perspectives. By providing a place ... to gain understanding, increase empathy, and find greater happiness. , "Our approach ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 2017 Juan Monteverde , founder and ... a boutique securities firm headquartered at the Empire State ... announces that a class action lawsuit has been filed in ...  against Inotek Pharmaceuticals Corporation (NASDAQ:  ITEK)("Inotek" or the "Company") ... 23, 2015 and December 30, 2016, inclusive (the "Class ...
(Date:2/24/2017)... Australien, 24. Februar 2017 ITL Limited, ... des Gesundheitsbereiches, ist erfreut, für das zum 31. ... entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. Eine ... zum Wachstum" finden Sie hier . ... nach Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)... -- This report analyzes the worldwide markets for Chiral Technology ... Products: Intermediates, Analytical, and Others. The End Use markets ... The report provides separate comprehensive analytics for the US, ... , and Rest of World. Annual estimates and forecasts ... a six-year historic analysis is provided for these markets. ...
Breaking Medicine Technology: